Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: A preliminary report

Antiviral Therapy

Volumn 17, Issue 6, 2012, Pages 1091-1096

  Goyal, Rohit ^a   Kumar, Ajay ^a   Panda, Subrat K ^a   Paul, Shashi B ^a   Acharya, Subrat K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; TENOFOVIR; VIRUS RNA;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CHRONIC LIVER FAILURE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; LIVER FUNCTION; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERINFECTION; TREATMENT DURATION; VIRUS DETECTION; VIRUS TYPING;

ADOLESCENT; ANTIVIRAL AGENTS; END STAGE LIVER DISEASE; FEMALE; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; LIVER FAILURE, ACUTE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84865791569     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2317     Document Type: Article

References (19)

1. Acharya SK, Panda SK, Hepatitis E. Virus: epidemiology, diagnosis, pathology and prevention. Trop Gastroenterol 2006; 27:63-68.
2. Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009; 3:269-282.
3. Ramachandran J, Eapen CE, Kang G, et al. Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease. J Gastroenterol Hepatol 2004; 19:134-138.
4. Monga R, Garg S, Tyagi P, Kumar N. Superimposed acute hepatitis E infection in patients with chronic liver disease. Indian J Gastroenterol 2004; 23:50-52.
5. Kumar A, Aggarwal R, Naik SR, Saraswat V, Ghoshal UC, Naik S. Hepatitis E virus is responsible for decompensation of chronic liver disease in an endemic region. Indian J Gastroenterol 2004; 23:59-62.
6. Kc S, Mishra AK, Shrestha R. Hepatitis E virus infection in chronic liver disease causes rapid decompensation. JNMA J Nepal Med Assoc 2006; 45:212-215.
7. Acharya SK, Sharma PK, Singh R, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007; 46:387-394.
8. Mallet V, Nicand E, Sultanik P, et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 2010; 153:85-89.
9. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication in patients with chronic hepatitis E virus infection. Gastroenterology 2010; 139:1612-1618.
10. Chaillon A, Sirinelli A, De Muret A, Nicand E, d'Alteroche L, Goudeau A. Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation. J Heart Lung Transplant 2011; 30:841-843.
11. Péron JM, Dalton H, Izopet J, Kamar N. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin? J Hepatol 2011; 54:1323-1324.
12. Aggarwal R, Naik S. Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol 2009; 24:1484-1493.
13. Jameel S, Durgapal H, Habibullah CM, Khuroo MS, Panda SK. Enteric nonA, nonB hepatitis: epidemics, animal transmission and hepatitis E virus detection by the polymerase chain reaction. J Med Virol 1992; 37:263-270.
14. Acharya SK, Panda SK. Hepatitis E: water, water everywhere - now a global disease. J Hepatol 2011; 54:9-11.
15. Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006; 57:8-13.
16. Bougie I, Bisaillon M. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 2004; 279:22124-22130.
17. Graci JD, Cameron CE. Therapeutically targeting RNA viruses via lethal mutagenesis. J Future Virol 2008; 3:553-566.
18. Cannon NA, Donlin MJ, Mayes LM, Lyra AC, Di Bisceglie AM, Tavis JE. Evidence for action of ribavirin through hepatitis C virus RNA polymerase. J Viral Hepat 2009; 16:595-604.
19. Tsai SL, Sheen TI, Chien RN, et al. Activation of TH1 immunity is common immune mechanism for successful treatment of hepatitis B and C: treatment assay and therapeutic implications. J Biomed Sci 2003; 10:120-135.